Literature DB >> 16684018

SCN5A mutation associated with cardiac conduction defect and atrial arrhythmias.

Päivi J Laitinen-Forsblom1, Pekka Mäkynen, Heikki Mäkynen, Sinikka Yli-Mäyry, Vesa Virtanen, Kimmo Kontula, Katriina Aalto-Setälä.   

Abstract

INTRODUCTION: We aimed at identifying the molecular defect underlying the clinical phenotype of a Finnish family with a cardiac conduction defect and atrial arrhythmias. METHODS AND
RESULTS: A large Finnish family was clinically evaluated (ECG, 24-hour ambulatory ECG, echocardiography). We performed linkage analysis with markers flanking the SCN5A gene and subsequently sequenced the SCN5A gene. Five family members had atrial arrhythmias and intracardiac conduction defects, and due to bradycardia needed a pacemaker when adolescents. No heart failure or sudden cardiac death was observed. Left ventricle dilatation was seen in one individual and three individuals had a slightly enlarged right ventricle. Premature death due to stroke occurred in one subject during the study, and two other members had suffered from stroke at young age. Linkage analysis favored the role of the SCN5A gene in disease pathogenesis, and direct sequencing disclosed D1275N mutation. This alteration was present not only in all six affected individuals, but also in two young individuals lacking clinical symptoms.
CONCLUSIONS: Cardiac conduction defect and atrial arrhythmias in a large Finnish family appear to result from the SCN5A D1275N mutation. Although no sudden cardiac death was recorded in the family, at least three affected members had encountered brain infarction at the age of 30 or younger.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684018     DOI: 10.1111/j.1540-8167.2006.00411.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  28 in total

1.  Ion channel mutations in AF: signal or noise?

Authors:  Patrick T Ellinor; Calum A MacRae
Journal:  Heart Rhythm       Date:  2008-01-17       Impact factor: 6.343

Review 2.  Emerging directions in the genetics of atrial fibrillation.

Authors:  Nathan R Tucker; Patrick T Ellinor
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

3.  Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro.

Authors:  Hiroshi Watanabe; Tao Yang; Dina Myers Stroud; John S Lowe; Louise Harris; Thomas C Atack; Dao W Wang; Susan B Hipkens; Brenda Leake; Lynn Hall; Sabina Kupershmidt; Nagesh Chopra; Mark A Magnuson; Naohito Tanabe; Björn C Knollmann; Alfred L George; Dan M Roden
Journal:  Circulation       Date:  2011-08-08       Impact factor: 29.690

Review 4.  The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight?

Authors:  Dawood Darbar
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

Review 5.  Genetics of atrial fibrillation: from families to genomes.

Authors:  Ingrid E Christophersen; Patrick T Ellinor
Journal:  J Hum Genet       Date:  2015-05-21       Impact factor: 3.172

Review 6.  Genetics and Sinus Node Dysfunction.

Authors:  Eyal Nof; Michael Glikson; Charles Antzelevitch
Journal:  J Atr Fibrillation       Date:  2009-04-01

Review 7.  Translating emerging molecular genetic insights into clinical practice in inherited cardiomyopathies.

Authors:  Babken Asatryan; Argelia Medeiros-Domingo
Journal:  J Mol Med (Berl)       Date:  2018-08-20       Impact factor: 4.599

8.  Multiple loss-of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome.

Authors:  Junhong Gui; Tao Wang; Richard P O Jones; Dorothy Trump; Thomas Zimmer; Ming Lei
Journal:  PLoS One       Date:  2010-06-07       Impact factor: 3.240

Review 9.  Genetic mechanisms of atrial fibrillation: impact on response to treatment.

Authors:  Dawood Darbar; Dan M Roden
Journal:  Nat Rev Cardiol       Date:  2013-04-16       Impact factor: 32.419

Review 10.  The cardiac sodium channel gene SCN5A and its gene product NaV1.5: Role in physiology and pathophysiology.

Authors:  Christiaan C Veerman; Arthur A M Wilde; Elisabeth M Lodder
Journal:  Gene       Date:  2015-09-08       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.